Sentence examples for biomarker data can be from inspiring English sources

By performing tumour and/or normal tissue biopsies before and after drug administration, useful biomarker data can be generated.

For whole effluent assessment, biomarker data can be used to design cost-effective biological and chemical monitoring programs to reduce ecological impacts in receiving waters.

Advantages of studying biochemical biomarkers in animal models of OA include availability of biospecimens before injury and at precise intervals after injury where biomarker data can be correlated with structural information obtained from gross and histological evaluations.

Using biomarkers to drive tumor growth inhibition enables a quantitative assessment of the relationship between biomarker and tumor growth inhibition, which may guide dose regimen selection in the clinic if similar biomarker data can be obtained.

In this article, we aim to show how biomarker data can be used as a bridge in exposure response analysis to estimate clinical endpoint response at certain dose levels when the direct relationship between exposure and the clinical endpoint can not be quantified reliably.

Specifically, we aim to show how biomarker data can be used as a bridge in exposure response analysis to estimate the clinical endpoint response at certain doses when the direct relationship between exposure and the clinical endpoint can not be quantified reliably.

Biomarker technologies that generate quantitative data, can be performed on small amounts of tissue (e.g. tumor biopsies), are multiplexable and/or allow for in vivo or minimally invasive assessment are particularly attractive.

However, serious concerns have been raised because very few molecular biomarkers or signatures discovered from high dimensional array data can be successfully validated and applied to clinical use.

These data can be leveraged to help identify potential biomarkers and drivers of progression of clinically significant disease.

Collectively, our results indicate that admission microarray data can be used to identify novel candidate biomarkers for SSAKI.

We emphasize the incorporation of PD assessment into early clinical trial design, providing a breakdown of PD biomarker data that can be realistically obtained at each trial phase and a framework for constructing clinical protocols to include PD biomarker studies.